<div id="readability-page-1"><p>Lemaitre Vascular ((LMAT)) has held its Q4 earnings call. Read on for the main highlights of the call.</p><h3>Claim 50% Off TipRanks Premium</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  and maximize your portfolio's potential</li></ul> <p>LeMaitre Vascular’s latest earnings call struck a notably upbeat tone, underscoring strong revenue growth, widening margins and powerful cash generation. Management balanced this optimism with transparency on a recent cyber incident, manufacturing consolidation costs and regulatory delays, but insisted these issues are manageable and already reflected in guidance.</p> <h2>Strong Q4 and Full-Year Revenue Momentum</h2> <p>LeMaitre delivered Q4 sales growth of 16% year-over-year, with organic revenue up 15% driven by 9% price and 6% unit gains. For full-year 2025, organic revenue climbed 14%, helped by standout regional performances in EMEA at 29% growth, APAC at 20% and the Americas at 10%.</p> <h2>Margin Expansion and Operating Leverage</h2> <p>Profitability improved sharply as Q4 gross margin rose 240 basis points to 71.7%, powering a 47% jump in operating income to $18.8 million and a 29% operating margin. For 2025, adjusted gross margin reached 70.4% and adjusted operating margin hit 26%, showcasing meaningful operating leverage as sales scale.</p> <h2>EPS Growth and Robust Cash Generation</h2> <p>Fourth-quarter diluted EPS increased 39% to $0.68, despite a $0.5 million one-time mark-to-market investment loss that weighed on the bottom line. LeMaitre ended the year with $359 million in cash and securities and generated $74.5 million of free cash flow, giving it ample financial flexibility.</p> <h2>Confident 2026 Outlook and Growth Algorithm</h2> <p>Management laid out 2026 guidance calling for $280 million in revenue, implying roughly 12% organic growth with continued margin gains. They forecast a 72.1% gross margin, operating income of $77.8 million and adjusted EPS of $2.91, assuming stable euro-dollar rates and a 4% yield on the company’s sizable cash balance.</p> <h2>Broad-Based Product Strength Across the Portfolio</h2> <p>The quarter’s growth was fueled by strong demand across key product lines, including grafts up 27%, valvulotomes up 20% and shunts up 18%. Radiofrequency ablation also performed well, with vascular RFA rising 19% and the smaller cardiac RFA line surging 90% off a low base.</p> <h2>Artegraft Launch Exceeds Expectations</h2> <p>Artegraft was a standout, growing 29% worldwide in Q4 and gaining traction internationally with $1.9 million in Q4 sales and $4 million for 2025. With approvals now in 52 countries, LeMaitre lifted its outlook for international Artegraft to about $10 million in 2026 and expanded its estimated market size to roughly $30 million.</p> <h2>Capital Returns: Buybacks and Dividend Growth</h2> <p>The board authorized a $100 million share repurchase program, signaling confidence in the company’s valuation and long-term prospects. LeMaitre also raised its Q1 2026 dividend to $0.25 per share, a 25% year-over-year increase and its 15th consecutive annual dividend hike.</p> <h2>Sales Force Investment and Direct Market Push</h2> <p>LeMaitre ended 2025 with 160 sales representatives, up 5%, and plans to reach 170–180 by the end of 2026 to support its growth plan. The company is moving to a direct model in Poland and expanding its direct-to-hospital footprint to a 32nd country, aiming for tighter customer relationships and better pricing power.</p> <h2>European Regulatory Progress Under MDR</h2> <p>In Europe, LeMaitre secured final MDR approval for PTFE LifeSpan and reported broad regulatory progress, reinforcing strong regional momentum. Management cited 17% organic growth in Europe for the full year, indicating that regulatory wins are translating into commercial traction.</p> <h2>January Cyber Incident Contained</h2> <p>A cyber incident in January 2026 affected certain systems and data, but management said critical systems have been securely restored with limited disruption to sales and manufacturing. They believe insurance coverage is adequate and emphasized that the estimated financial impact is already embedded in 2026 guidance.</p> <h2>Manufacturing Consolidation and Near-Term Cost Headwinds</h2> <p>LeMaitre plans to consolidate its Chicago RFA facility into Burlington and transfer RestoreFlow processing there in 2026, a move aimed at longer-term efficiency. In the near term, the company expects a modest gross margin headwind and about $11 million of capital spending, with some cost pressure skewed to the back half of the year.</p> <h2>One-Time Investment Loss Already Behind Them</h2> <p>Q4 EPS was impacted by a $0.5 million mark-to-market loss on an investment, which management flagged as non-recurring. The investment has since been sold, suggesting less earnings volatility from this source going forward and reinforcing the underlying strength of core operations.</p> <h2>Regulatory Timing Slippage in Ireland</h2> <p>The company’s RestoreFlow approval in Ireland has slipped from an expected sign-off by the end of Q2 to Q3 2026 due to filing delays into March. While this pushes out the timeline slightly, management framed it as a timing issue rather than a change in the long-term opportunity.</p> <h2>Growth Mix: Modest Units, Strong Pricing</h2> <p>Full-year 2025 unit growth came in at 5%, while pricing contributed 9 percentage points of organic revenue growth, showing that price increases were a big driver. Investors may watch whether unit volumes can accelerate over time, as the current growth mix leans heavily on pricing power.</p> <h2>APAC Growth With Pockets of Softness</h2> <p>APAC delivered 20% growth in Q4, but management noted softness in Japan and lingering effects from prior catheter issues in Korea, which are now resolved. China remains a small but profitable and growing business of around $2 million in sales, offering incremental upside as it scales.</p> <h2>Slow Uptake From Some New Approvals</h2> <p>Not all regulatory wins are paying off immediately, as seen with XenoSure cardiac’s approval in China, which management characterized as a “big nothing burger” so far. The commentary underscored that some approvals may take time to convert into meaningful revenue and should be viewed as longer-term options.</p> <h2>Forward-Looking Guidance and Strategic Priorities</h2> <p>For 2026, LeMaitre projects $280 million in revenue with about 12% organic growth, continued gross margin expansion to 72.1% and 21% adjusted operating income growth. Guidance includes roughly $10 million in international Artegraft sales, a larger sales force, elevated capital spending and already factors in the expected impact of the recent cyber incident.</p> <p>LeMaitre’s earnings call painted the picture of a specialty medtech company hitting its stride, with strong growth, rising margins and disciplined capital returns. While cyber risk, consolidation costs and regulatory timing remain watch points, management’s confident guidance and robust cash position suggest the growth story has room to run for shareholders.</p></div>

LMAT

<p>LeMaitre Vascular's Q4 earnings call highlighted strong revenue growth, with a 16% year-over-year increase and a 39% rise in diluted EPS to $0.68. The company reported a gross margin of 71.7% and plans for $280 million in revenue for 2026, projecting 12% organic growth. A $100 million share repurchase program was authorized, and the dividend was raised by 25%. Despite a recent cyber incident and regulatory delays, management remains optimistic about future growth, particularly with the Artegraft product line and European market expansion.</p>

LeMaitre Vascular Signals Confident Growth in Earnings Call